{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:23:56Z","timestamp":1781677436462,"version":"3.54.5"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":3016,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Furosemide is the only loop diuretic recommended by the ACVIM consensus guidelines for treatment of congestive heart failure (CHF) in dogs related to degenerative mitral valve disease (DMVD). Torasemide is another potent loop diuretic with a longer half-life and a higher bioavailability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>(1) To demonstrate that torasemide given once a day (q24h) is noninferior to furosemide given twice a day (q12h) for treating dogs with CHF; (2) and to compare the effect of the 2 drugs on the time to reach a composite cardiac endpoint \u201cspontaneous cardiac death, euthanasia due to heart failure or CHF class worsening.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>A total of 366 dogs with CHF attributable to DMVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analysis of 2 prospective randomized single-blinded reference-controlled trials was performed. Dogs orally received either torasemide q24h (n\u00a0=\u00a0180) or furosemide q12h (n\u00a0=\u00a0186) in addition to standard CHF therapy over 3\u00a0months. The primary efficacy criterion was the percentage of dogs with treatment success assessed in each study. The time to reach the composite cardiac endpoint was used as secondary criterion in the overall population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Torasemide was noninferior to furosemide (Ptorasemide\u00a0\u2212\u00a0Pfurosemide\u00a0=\u00a0+7%; 95% CI [\u22128%; +22%] and Ptorasemide\u00a0\u2212\u00a0Pfurosemide\u00a0=\u00a0+1%; 95% CI [\u221212%; +14%], respectively, in Study 1 and Study 2). Torasemide (median dose\u00a0=\u00a00.24\u00a0mg\/kg\/d q24h; range\u00a0=\u00a00.10\u20130.69\u00a0mg\/kg\/d) was associated with a 2-fold reduction in the risk of reaching the composite cardiac endpoint (adjusted HR\u00a0=\u00a00.47; 95% CI\u00a0=\u00a00.27\u20130.82; P\u00a0=\u00a00.0077) as compared with furosemide (median dose\u00a0=\u00a01.39\u00a0mg\/kg q12h; range\u00a0=\u00a00.70\u20136.30\u00a0mg\/kg q12h).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Torasemide q24h is an effective oral diuretic in dogs with CHF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14841","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T06:16:52Z","timestamp":1507097812000},"page":"1629-1642","source":"Crossref","is-referenced-by-count":31,"title":["Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study"],"prefix":"10.1093","volume":"31","author":[{"given":"V.","family":"Chetboul","sequence":"first","affiliation":[{"name":"Alfort Cardiology Unit, Universit\u00e9 Paris-Est, Ecole Nationale V\u00e9t\u00e9rinaire d'Alfort , Maisons-Alfort Cedex,","place":["France"]},{"name":"INSERM U955, Equipe 03 , Cr\u00e9teil Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Pouchelon","sequence":"additional","affiliation":[{"name":"Alfort Cardiology Unit, Universit\u00e9 Paris-Est, Ecole Nationale V\u00e9t\u00e9rinaire d'Alfort , Maisons-Alfort Cedex,","place":["France"]},{"name":"INSERM U955, Equipe 03 , Cr\u00e9teil Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Menard","sequence":"additional","affiliation":[{"name":"Vetoquinol SA , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Blanc","sequence":"additional","affiliation":[{"name":"Vetoquinol SA , Lure,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Desquilbet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Est, Ecole Nationale V\u00e9t\u00e9rinaire d'Alfort Department of Biostatistics and Clinical Epidemiology, , Maisons-Alfort Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Petit","sequence":"additional","affiliation":[{"name":"Alfort Cardiology Unit, Universit\u00e9 Paris-Est, Ecole Nationale V\u00e9t\u00e9rinaire d'Alfort , Maisons-Alfort Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rougier","sequence":"additional","affiliation":[{"name":"Vetoquinol SA , Lure,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lucats","sequence":"additional","affiliation":[{"name":"Vetoquinol SA , Lure,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Woehrle","sequence":"additional","affiliation":[{"name":"Vetoquinol SA , Lure,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Woehrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"2026020303231425900_jvim14841-bib-0001","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure)","volume":"38","author":"Hunt","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0002","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0003","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jvc.2012.02.002","article-title":"Pharmacologic management of myxomatous mitral valve disease in dogs","volume":"14","author":"Atkins","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0005","first-page":"94","article-title":"Left-sided congestive heart failure in dogs: Treatment and monitoring of emergency patients","volume":"30","author":"Erling","year":"2008","journal-title":"Compend Contin Educ Vet"},{"key":"2026020303231425900_jvim14841-bib-0006","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cvsm.2013.03.012","article-title":"Management of cardiac emergencies in small animals","volume":"43","author":"DeFrancesco","year":"2013","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020303231425900_jvim14841-bib-0007","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s40138-013-0012-8","article-title":"Acute heart failure treatment","volume":"1","author":"Levy","year":"2013","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"2026020303231425900_jvim14841-bib-0008","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4037\/ajcc2003.12.4.376","article-title":"Diuretics, the most critical therapy in heart failure, yet often neglected in the literature","volume":"12","author":"Futterman","year":"2003","journal-title":"Am J Crit Care"},{"key":"2026020303231425900_jvim14841-bib-0009","first-page":"4","article-title":"Disposition kinetics of furosemide in dogs","volume":"253","author":"El-Sayed","year":"1981","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2026020303231425900_jvim14841-bib-0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: A review and update","volume":"19","author":"Roush","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026020303231425900_jvim14841-bib-0011","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1345\/aph.1M177","article-title":"A comprehensive review of the loop diuretics: Should furosemide be first line?","volume":"43","author":"Wargo","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2026020303231425900_jvim14841-bib-0012","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","article-title":"A reappraisal of loop diuretic choice in heart failure patients","volume":"169","author":"Buggey","year":"2015","journal-title":"Am Heart J"},{"key":"2026020303231425900_jvim14841-bib-0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1748-5827.1985.tb02199.x","article-title":"Observations on breed and sex in relation to canine heart valve incompetence","volume":"26","author":"Thrusfield","year":"1985","journal-title":"J Small Anim Pract"},{"key":"2026020303231425900_jvim14841-bib-0014","first-page":"1022","article-title":"Textbook of Veterinary Internal Medicine","author":"Kvart","year":"2005","edition":"6"},{"key":"2026020303231425900_jvim14841-bib-0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2460\/javma.1993.203.07.1023","article-title":"Chronic mitral valve disease in Cavalier King Charles spaniels: 95 cases (1987\u20131991)","volume":"203","author":"Beardow","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303231425900_jvim14841-bib-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvc.2005.10.001","article-title":"Retrospective study of 942 small sized-dogs: Prevalence of left apical systolic heart murmur and left-sided heart failure, critical effects of breed, and sex","volume":"8","author":"Serfass","year":"2006","journal-title":"J Vet Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0017","first-page":"1012","article-title":"Epidemiological, clinical, echo-doppler characteristics of mitral valve endocardiosis in Cavalier King Charles in France: A retrospective study of 451 cases (1995 to 2003)","volume":"45","author":"Chetboul","year":"2004","journal-title":"Can Vet J"},{"key":"2026020303231425900_jvim14841-bib-0018","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1292\/jvms.65.1057","article-title":"The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats","volume":"65","author":"Uechi","year":"2003","journal-title":"J Vet Med Sci"},{"key":"2026020303231425900_jvim14841-bib-0019","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2460\/ajvr.68.10.1058","article-title":"Effects of oral administration of furosemide and torsemide in healthy dogs","volume":"68","author":"Hori","year":"2007","journal-title":"Am J Vet Res"},{"key":"2026020303231425900_jvim14841-bib-0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/vec.12301","article-title":"Comparison of the diuretic effect of furosemide by different methods of administration in healthy dogs","volume":"25","author":"Harada","year":"2015","journal-title":"J Vet Emerg Crit Care (San Antonio)"},{"key":"2026020303231425900_jvim14841-bib-0021","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/187152908784533685","article-title":"Torasemide for the treatment of heart failure","volume":"8","author":"Ishido","year":"2008","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"2026020303231425900_jvim14841-bib-0022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2217\/fca.12.54","article-title":"Should torsemide be the loop diuretic of choice in systolic heart failure?","volume":"8","author":"DiNicolantonio","year":"2012","journal-title":"Future Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/FJC.0b013e3181a71a78","article-title":"Loop diuretics in patients with heart failure: Time to change to torsemide?","volume":"53","author":"Pitt","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020303231425900_jvim14841-bib-0024","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jacc.2012.12.043","article-title":"Dominance of furosemide for loop diuretic therapy in heart failure: Time to revisit the alternatives?","volume":"61","author":"Bikdeli","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/j.1875-9114.1994.tb02848.x","article-title":"Oral torsemide in patients with chronic congestive heart failure: Effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group","volume":"14","author":"Patterson","year":"1994","journal-title":"Pharmacotherapy"},{"key":"2026020303231425900_jvim14841-bib-0026","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: Results of the TORIC study","volume":"4","author":"Cos\u00edn","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2026020303231425900_jvim14841-bib-0027","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1586\/erc.09.74","article-title":"TORAFIC study protocol: Torasemide prolonged release versus furosemide in patients with chronic heart failure","volume":"7","author":"D\u00edez","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026020303231425900_jvim14841-bib-0028","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1388-9842(03)00150-8","article-title":"Torasemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV \u2013 efficacy and quality of life","volume":"5","author":"Muller","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026020303231425900_jvim14841-bib-0029","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.2042-7158.1996.tb05936.x","article-title":"Urinary excretion profile of torasemide and its diuretic action in dogs","volume":"48","author":"Sogame","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"2026020303231425900_jvim14841-bib-0030","first-page":"293","article-title":"Diuretic profile of a novel loop diuretic torasemide in rats and dogs","volume":"17","author":"Uchida","year":"1991","journal-title":"Drugs Exp Clin Res"},{"key":"2026020303231425900_jvim14841-bib-0031","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1440-1681.1991.tb01483.x","article-title":"Effects of torasemide on renal haemodynamics and function in anaesthetized dogs","volume":"18","author":"Uchida","year":"1991","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026020303231425900_jvim14841-bib-0032","first-page":"1431","article-title":"Torasemide. Plumb's Veterinary Drug Handbook","author":"Plumb","year":"2015","edition":"8"},{"key":"2026020303231425900_jvim14841-bib-0033","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000176452","article-title":"Diuretic and vasodilating actions of torasemide","volume":"84","author":"Uchida","year":"1994","journal-title":"Cardiology"},{"key":"2026020303231425900_jvim14841-bib-0034","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0952-3278(92)90227-A","article-title":"A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery","volume":"45","author":"Uchida","year":"1992","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026020303231425900_jvim14841-bib-0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1253\/circj.67.384","article-title":"Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure","volume":"67","author":"Yamato","year":"2003","journal-title":"Circ J"},{"key":"2026020303231425900_jvim14841-bib-0036","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/FJC.0b013e3181a717f7","article-title":"Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: Comparison with azosemide","volume":"53","author":"Harada","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020303231425900_jvim14841-bib-0037","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jacc.2007.04.080","article-title":"Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure","volume":"5","author":"L\u00f3pez","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0038","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure","volume":"43","author":"L\u00f3pez","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0039","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/hrt.2005.079764","article-title":"Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure","volume":"92","author":"Kasama","year":"2006","journal-title":"Heart"},{"key":"2026020303231425900_jvim14841-bib-0040","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.jacc.2004.09.009","article-title":"Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure","volume":"44","author":"Tsutamoto","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0041","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.4238\/2014.September.5.11","article-title":"Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure","volume":"13","author":"Han","year":"2014","journal-title":"Genet Mol Res"},{"key":"2026020303231425900_jvim14841-bib-0042","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.yjmcc.2015.05.019","article-title":"Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice","volume":"85","author":"Adam","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0043","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0014-2999(91)90812-5","article-title":"Anti-aldosteronergic effect of torasemide","volume":"205","author":"Uchida","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"2026020303231425900_jvim14841-bib-0044","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bcp.2007.09.026","article-title":"Comparative effects of torasemide and furosemide in rats with heart failure","volume":"75","author":"Veeraveedu","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"2026020303231425900_jvim14841-bib-0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2007.11.034","article-title":"Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy","volume":"581","author":"Veeraveedu","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2026020303231425900_jvim14841-bib-0046","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/S0024-3205(98)00265-3","article-title":"Torsemide inhibits aldosterone secretion in\u00a0vitro","volume":"63","author":"Goodfriend","year":"1998","journal-title":"Life Sci"},{"key":"2026020303231425900_jvim14841-bib-0047","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/vr.160.24.847","article-title":"Effect of torsemide on serum and urine electrolyte levels in dogs with congestive heart failure","volume":"160","author":"Caro-Vadillo","year":"2007","journal-title":"Vet Rec"},{"key":"2026020303231425900_jvim14841-bib-0048","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jvc.2011.10.001","article-title":"Use of the loop diuretic torsemide in three dogs with advanced heart failure","volume":"13","author":"Oyama","year":"2011","journal-title":"J Vet Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0049","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jvc.2012.01.003","article-title":"Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease","volume":"14","author":"Peddle","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0050","article-title":"VICH Topic GL9, Good Clinical Practices (CVMP\/VICH\/595\/98-FINAL)."},{"key":"2026020303231425900_jvim14841-bib-0051","article-title":"Guideline on statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals)","author":"EMA\/CVMP\/EWP\/81976\/2010"},{"key":"2026020303231425900_jvim14841-bib-0052","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jvc.2011.11.005","article-title":"Echocardiographic assessment of canine degenerative mitral valve disease","volume":"14","author":"Chetboul","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0053","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1740-8261.2002.tb01051.x","article-title":"Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement","volume":"43","author":"Hansson","year":"2002","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020303231425900_jvim14841-bib-0054","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0055","first-page":"692","article-title":"Pathophysiology of Heart Failure and Clinical Evaluation of Cardiac Function. Textbook of Veterinary Internal Medicine","author":"Autran de Morais","year":"2000","edition":"5"},{"key":"2026020303231425900_jvim14841-bib-0056","first-page":"1990","article-title":"Chronic Kidney Disease. Textbook of Veterinary Internal Medicine","author":"Polzin","year":"2010","edition":"7"},{"key":"2026020303231425900_jvim14841-bib-0057","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomised, double-blinded, placebo-controlled, long-term clinical trial","volume":"1","author":"Pouchelon","year":"1999","journal-title":"J Vet Cardiol"},{"key":"2026020303231425900_jvim14841-bib-0058","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1939-1676.1995.tb01074.x","article-title":"Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study","volume":"9","author":"The IMPROVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0059","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the Cooperative Veterinary Enalapril Study Group","volume":"9","author":"The COVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0060","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303231425900_jvim14841-bib-0061","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/jvim.12181","article-title":"Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: The QUEST study","volume":"27","author":"H\u00e4ggstr\u00f6m","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0062","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0063","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/jvim.12141","article-title":"Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: A population-based, longitudinal study","volume":"27","author":"Lefebvre","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0064","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jvim.12564","article-title":"Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease","volume":"29","author":"Borgarelli","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020303231425900_jvim14841-bib-0065","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2460\/javma.229.11.1772","article-title":"Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001\u20132005)","volume":"229","author":"Serres","year":"2006","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303231425900_jvim14841-bib-0066","doi-asserted-by":"crossref","first-page":"e73737","DOI":"10.1371\/journal.pone.0073737","article-title":"The diuretic torasemide does not prevent aldosterone mineralocorticoid receptor activation in cardiomyocytes","volume":"8","author":"Gravez","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/6\/1629\/66668881\/jvim14841.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/6\/1629\/66668881\/jvim14841.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:23:29Z","timestamp":1770107009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/31\/6\/1629\/8449452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14841","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,11,1]]}}}